Susan K. Paulson

Akebia Therapeutics (United States) — United States

Medicine · Health Sciences

17h-index2.1kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(8), Antibiotics Pharmacokinetics and Efficacy(7), Antibiotic Resistance in Bacteria(6), Pharmacogenetics and Drug Metabolism(6), Vitamin D Research Studies(5)

Publications39 total

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
Clinical Pharmacology in Drug Development·2022· 6 citedOpen Access
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor
Clinical Pharmacology in Drug Development·2021· 15 cited
Pharmacokinetic Evaluation of Drug Interactions Between Vadadustat and HMG-CoA Reductase Inhibitors (Statins)
Journal of the American Society of Nephrology·2020· 1 cited
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
The Journal of Clinical Pharmacology·2018· 35 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease
The Journal of Clinical Pharmacology·2018· 16 cited
Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
The Journal of Clinical Pharmacology·2017· 32 citedOpen Access
The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin
Clinical Therapeutics·2017· 31 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2017Open Access
Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
The Journal of Clinical Pharmacology·2016· 35 citedOpen Access
Table of Contents
Clinical Therapeutics·2016Open Access
Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers
Clinical Therapeutics·2015· 53 citedOpen Access
Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age
Clinical Therapeutics·2015· 49 citedOpen Access
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
Inflammatory Bowel Diseases·2013· 122 citedOpen Access
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Annals of Internal Medicine·2012· 9 cited
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Annals of Internal Medicine·2012· 406 cited
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Journal of Crohn s and Colitis·2011· 148 citedOpen Access
741 Evaluation of Potential Correlations Between Serum Adalimumab Concentration and Remission in Patients With Crohn's Disease in Classic I and II
Gastroenterology·2010· 10 citedOpen Access
Disposition and Pharmacokinetics of L-N6-(1-Iminoethyl)Lysine-5-Tetrazole-Amide, a Selective iNOS Inhibitor, in Rats
Journal of Pharmaceutical Sciences·2004· 14 cited
page 1 of 2Next →

Frequent Co-authors

Randall Hoover(11), Laura Lawrence(11), Sue Cammarata(11), Megan Quintas(8), Timothy J. Maziasz(7), Alan P. Breau(5), Harry Alcorn(5), Aziz Karim(4), Ji Y. Zhang(4), David R. Luke(4), Christopher J. Gresk(3), Kathleen G. Lomax(3), Grant L. Schoenhard(3), Earl G. Burton(3), Michael Benedict(3), Eugene Sun(3), Ajit Chavan(3), Rishikesh Sawant(3), Alexa B. Kimball(2), Francisco A. Kerdel(2)